Sierra Acai Company
Sierra Acai Company
Open 7 Days a Week
MonaVie Independent Distributor
Distributor Training
Shop Online
Enroll Now
Buy Wholesale and maintain an Active status for 2 months and we will refund your $39 Distributor Fee
Friends
Buy Wholesale and maintain an Active status for 2 months and we will refund your $39 Distributor Fee
20-September-2008 09:55:54 - receptor 1 Redirected from Knops antigen system August 2008 Complement component 3b/4b receptor 1 Knops blood group PDB rendering based on 1gkg. Available structures: 1gkg, 1gkn, 1ppq Identifiers Symbols CR1; C3BR; CD35; KN External IDs OMIM: 120620 HomoloGene: 55474 Gene ontology Molecular function: receptor activity complement component C3b receptor activity Cellular component: integral to plasma membrane membrane Biological process: complement activation, classical pathway innate immune response RNA expression pattern 250px 250px 250px More reference expression data Orthologs Human Mouse Entrez 1378 n/a Ensembl ENSG00000203710 n/a Uniprot P17927 n/a Refseq XM_001126036 mRNA XP_001126036 protein n/a mRNA n/a protein Location Chr 1: 205.74 - 205.88 Mb n/a Pubmed search 1 n/a Erythrocyte complement receptor 1 CR1, also known as CD35, C3b/C4b receptor and immune adherence receptor is a human gene.12 This protein encoded by this gene is a member of the receptors of complement activation RCA family and is located in the 'cluster RCA' region of chromosome 1. The gene encodes a monomeric single-pass type I membrane glycoprotein found on erythrocytes, leukocytes, glomerular podocytes, and splenic follicular dendritic cells. The Knops blood group system is a system of antigens located on this protein. The protein mediates cellular binding to particles and immune complexes that have activated complement. Decreases in expression of this protein and/or mutations in its gene have been associated with gallbladder carcinomas, mesangiocapillary glomerulonephritis, systemic lupus erythematosus and sarcoidosis. Mutations in this gene have also been associated with a reduction in Plasmodium falciparum rosetting, conferring protection against severe malaria. Alternate allele-specific splice variants, encoding different isoforms, have been characterized. Additional allele specific isoforms, including a secreted form, have been described but have not been fully characterized.1 In primates, CR1 serves as the main system for processing and clearance of complement opsonized immune complexes. It has been shown that CR1 can act as a negative regulator of the complement cascade, mediate immune adherence and phagocytosis and inhibit both the classic and alternative pathways. The number of CR1 molecules decreases with aging of erythrocytes in normal individuals and is also decreased in pathological conditions such as systemic lupus erythematosus SLE, HIV infection, some haemolytic anaemias and other conditions featuring immune complexes. Contents 1 1q32 region 2 Forms 3 Structure 4 Alleles 5 Rosetting 6 Role in blood Groups 7 References 8 Further reading 9 External links 1q32 region In humans, the CR1 gene is located at on the long arm of chromosome 1 at band 32 1q32 and lies within a complex of immunoregulatory genes. In 5'-3' order the genes in this region are: membrane cofactor protein - CR1- complement receptor type 2 - decay-accelerating factor - C4-binding protein. Membrane cofactor protein is a widely distributed C3b/C4b binding regulatory glycoprotein of the complement system; decay-accelerating factor DAF: CD55: Cromer antigen protects host cells from complement-mediated damage by regulating the activation of C3 convertases on host cell surfaces; complement receptor 2 is the C3d receptor. Factor H, another immunoregulatory protein, also maps to this location. Forms The most common form of the CR1 gene CR11 is composed of 38 exons spanning 133kb encoding a protein of 2039 amino acids and has a predicted molecular weight of 220 kDa. Large insertions and deletions have given rise to four structurally variant genes and some alleles may extend up to 160 kb and 9 additional exons. The transcription start site has been mapped to 111 bp upstream of the translation initiation codon ATG and there is another possible start site 29 bp further upstream. The promoter region lacks a distinct TATA box sequence. The gene is expressed principally on erythrocytes, monocytes, neutrophils and B cells but is also present on some T lymphocytes, mast cells and glomerular podocytes. The mean number of complement receptor 1 CR1 molecules on erythrocytes in normal individuals lies within the range of 100-1000 molecules per cell. Two codominant alleles exist - one controlling high and the other low expression. Homozygotes differ by a factor of 10-20: heterozygotes typically have 500-600 copies per erythrocyte. These two alleles appear to have originated before the divergence of the European and African populations. Structure The encoded protein has a 47 amino acid signal peptide, an extracellular domain of 1930 residues, a 25 residue transmembrane domain and a 43 amino acid C terminal cytoplasmic region. The leader sequence and 5'-untranslated region are contained in one exon. The large extracellular domain of CR1, which has 25 potential N-glycosylation sites, can be divided into 30 short consensus repeats SCRs also known as complement control protein repeats CCPs or sushi domains, each having 60 to 70 amino acids. The sequence homology between SCRs ranges between 60 to 99 percent. The transmembrane region is encoded by 2 exons and the cytoplasmic domain and the 3'-untranslated regions are coded for by two separate exons. The 30 or so SCRs are further grouped into four longer regions termed long homologous repeats LHRs each encoding approximately 45 kDa of protein and designated LHR-A, -B, -C, and -D. The first three have seven SCRs while LHR-D has 9 or more. Each LHR is composed of 8 exons and within an LHR, SCR 1, 5, and 7 are each encoded by a single exon, SCR 2 and 6 are each encoded by 2 exons, and a single exon codes for SCR 3 and 4. The LHR seem to have arisen as a result of unequal crossing over and the event that gave rise to LHR-B seems to have occurred within the fourth exon of either LHR-A or -C. To date the atomic structure have been solved for SCRs 15-16, 16 16-17. Alleles Four alleles are known with predicted protein molecular weights of 190 kDa, 220 kDa, 250 kDa and 280kDa are known. Multiple size variants 55kDa-220kDa are also found among non-human primates and a partial amino-terminal duplication CR1-like gene that encodes the short 55kDa-70kDa forms expressed on non human erythrocytes. These short CR1 forms, some of which are glycosylphosphatidylinositol GPI anchored, are expressed on erythrocytes and the 220kDa molecular weight CR1 form is expressed on monocytes. The gene including the repeats is highly conserved in primates possibly because of the ability of the repeats to bind complement. LHR-A binds preferentially to the complement component C4b: LHR-B and LHR-C bind to C3b and also, albeit with a lower affinity, to C4b. Curiously the human CR1 gene appears to have an unusual protein conformation but the significance of this finding is not clear. Rosetting Plasmodium falciparum erythrocyte membrane protein 1 PfEMP1 interacts with uninfected erythrocytes. This 'stickiness', known as rosetting, is believed to be a strategy used by the parasite to remain sequestered in the microvasculature to avoid destruction in the spleen and liver. Erythrocyte rosetting causes obstruction of the blood flow in microcapillaries. There is a direct interaction between PfEMP1 and a functional site of complement receptor type 1 on uninfected erythrocytes. Role in blood Groups The Knops antigen was the 25th blood group system recognized and consists of the single antigen York Yk a with the following allelic pairs: Knops Kn a and b McCoy McC a and b Swain-Langley Sl 1 and 2 The antigen is known to lie within the CR1 protein repeats and was first described in 1970 in a 37-year-old Caucasian woman. Racial differences exist in the frequency of these antigens: 98.5% and 96.7% of American Caucasians and Africans respectively are positive for McCa. 36% of a Mali population were Kna and 14% of exhibited the null or Helgeson phenotype compared with only 1% in the American population. The frequencies of McC b and Sl 2 are higher in Africans compared with Europeans and while the frequency of McC b was similar between Africans from the USA or Mali, the Sl b phenotype is significantly more common in Mali - 39% and 65% respectively. In Gambia the Sl 2/McCb phenotype appears to have been positively selected - presumably due to malaria. 80% of Papua New Guineans have the Helgeson phenotype and case control studies suggest this phenotype has a protective effect against severe malaria. References ^ a b Entrez Gene: CR1 complement component 3b/4b receptor 1 Knops blood group. ^ Moulds JM, Nickells MW, Moulds JJ, Brown MC, Atkinson JP May 1991. The C3b/C4b receptor is recognized by the Knops, McCoy, Swain-langley, and York blood group antisera. J. Exp. Med. 173 5: 1159-63. PMID 1708809. Further reading Ahearn JM, Fearon DT 1989. Structure and function of the complement receptors, CR1 CD35 and CR2 CD21. Adv. Immunol. 46: 183-219. PMID 2551147. Wong WW, Farrell SA 1991. Proposed structure of the F' allotype of human CR1. Loss of a C3b binding site may be associated with altered function. J. Immunol. 146 2: 656-62. PMID 1670949. Tuveson DA, Ahearn JM, Matsumoto AK, Fearon DT 1991. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. J. Exp. Med. 173 5: 1083-9. doi:10.1084/jem.173.5.1083. PMID 1708808. Moulds JM, Nickells MW, Moulds JJ, et al. 1991. The C3b/C4b receptor is recognized by the Knops, McCoy, Swain-langley, and York blood group antisera. J. Exp. Med. 173 5: 1159-63. doi:10.1084/jem.173.5.1159. PMID 1708809. Rao N, Ferguson DJ, Lee SF, Telen MJ 1991. Identification of human erythrocyte blood group antigens on the C3b/C4b receptor. J. Immunol. 146 10: 3502-7. PMID 1827486. Hourcade D, Miesner DR, Bee C, et al. 1990. Duplication and divergence of the amino-terminal coding region of the complement receptor 1 CR1 gene. An example of concerted horizontal evolution within a gene. J. Biol. Chem. 265 2: 974-80. PMID 2295627. Reynes M, Aubert JP, Cohen JH, et al. 1985. Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J. Immunol. 135 4: 2687-94. PMID 2411809. Hinglais N, Kazatchkine MD, Mandet C, et al. 1989. Human liver Kupffer cells express CR1, CR3, and CR4 complement receptor antigens. An immunohistochemical study. Lab. Invest. 61 5: 509-14. PMID 2478758. Fearon DT, Klickstein LB, Wong WW, et al. 1989. Immunoregulatory functions of complement: structural and functional studies of complement receptor type 1 CR1; CD35 and type 2 CR2; CD21. Prog. Clin. Biol. Res. 297: 211-20. PMID 2531419. Wong WW, Cahill JM, Rosen MD, et al. 1989. Structure of the human CR1 gene. Molecular basis of the structural and quantitative polymorphisms and identification of a new CR1-like allele. J. Exp. Med. 169 3: 847-63. doi:10.1084/jem.169.3.847. PMID 2564414. Wong WW, Kennedy CA, Bonaccio ET, et al. 1986. Analysis of multiple restriction fragment length polymorphisms of the gene for the human complement receptor type I. Duplication of genomic sequences occurs in association with a high molecular mass receptor allotype. J. Exp. Med. 164 5: 1531-46. doi:10.1084/jem.164.5.1531. PMID 2877046. Wong WW, Klickstein LB, Smith JA, et al. 1985. Identification of a partial cDNA clone for the human receptor for complement fragments C3b/C4b. Proc. Natl. Acad. Sci. U.S.A. 82 22: 7711-5. doi:10.1073/pnas.82.22.7711. PMID 2933745. Klickstein LB, Wong WW, Smith JA, et al. 1987. Human C3b/C4b receptor CR1. Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J. Exp. Med. 165 4: 1095-112. doi:10.1084/jem.165.4.1095. PMID 2951479. Moldenhauer F, David J, Fielder AH, et al. 1987. Inherited deficiency of erythrocyte complement receptor type 1 does not cause susceptibility to systemic lupus erythematosus. Arthritis Rheum. 30 9: 961-6. doi:10.1002/art.1780300901. PMID 2959289. Hourcade D, Miesner DR, Atkinson JP, Holers VM 1988. Identification of an alternative polyadenylation site in the human C3b/C4b receptor complement receptor type 1 transcriptional unit and prediction of a secreted form of complement receptor type 1. J. Exp. Med. 168 4: 1255-70. doi:10.1084/jem.168.4.1255. PMID 2971757. Klickstein LB, Bartow TJ, Miletic V, et al. 1988. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor CR1, CD35 by deletion mutagenesis. J. Exp. Med. 168 5: 1699-717. doi:10.1084/jem.168.5.1699. PMID 2972794. Hing S, Day AJ, Linton SJ, et al. 1989. Assignment of complement components C4 binding protein C4BP and factor H FH to human chromosome 1q, using cDNA probes. Ann. Hum. Genet. 52 Pt 2: 117-22. doi:10.1111/j.1469-1809.1988.tb01086.x. PMID 2977721. Fearon DT 1985. Human complement receptors for C3b CR1 and C3d CR2. J. Invest. Dermatol. 85 1 Suppl: 53s-57s. doi:10.1111/1523-1747.ep12275473. PMID 2989379. Wilson JG, Murphy EE, Wong WW, et al. 1986. Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes. J. Exp. Med. 164 1: 50-9. doi:10.1084/jem.164.1.50. PMID 3014040. External links MeSH CR1+protein,+human MeSH Receptors,+Complement+3b Knops blood group system at BGMUT Blood Group Antigen Gene Mutation Database at NCBI, NIH v d e Proteins: clusters of differentiation see also list of human clusters of differentiation 1-50 CD1 a-c, 1A, 1D, 1E - CD2 - CD3 γ, δ, ε - CD4 - CD5 - CD6 - CD7 - CD8 a - CD9 - CD10 - CD11 a, b, c - CD13 - CD14 - CD15 - CD16 A, B - CD18 - CD19 - CD20 - CD21 - CD22 - CD23 - CD24 - CD25 - CD26 - CD27 - CD28 - CD29 - CD30 - CD31 - CD32 A, B - CD33 - CD34 - CD35 - CD36 - CD37 - CD38 - CD39 - CD40 - CD41- CD42 a, b, c, d - CD43 - CD44 - CD45 - CD46 - CD47 - CD48 - CD49 a, b, c, d, e, f - CD50 51-100 CD51 - CD52 - CD53 - CD54 - CD55 - CD56 - CD57- CD58 - CD59 - CD61 - CD62 E, L, P - CD63 - CD64 - CD66 a, b, c, d, e, f - CD68 - CD69 - CD70 - CD71 - CD72 - CD73 - CD74 - CD79 a, b - CD80 - CD81 - CD82 - CD83 - CD84 - CD85 a, d, e, h, j, k - CD86 - CD87 - CD88 - CD89 - CD90 - CD91- CD92 - CD93 - CD94 - CD95 - CD97 - CD98 - CD99 - CD100 101-150 CD101 - CD102 - CD103 - CD104 - CD105 - CD106 - CD107 a, b - CD108 - CD109 - CD110 - CD111 - CD112 - CD113 - CD114 - CD115 - CD116 - CD117 - CD118 - CD119 - CD120 a, b - CD121 a, b - CD122 - CD123 - CD124 - CD125 - CD126 - CD127 - CD129 - CD130 - CD131 - CD132 - CD133 - CD134 - CD135 - CD136 - CD137 - CD138 - CD140b - CD141 - CD142 - CD143 - CD144 - CD146 - CD147 - CD148 - CD150 151-200 CD151 - CD152 - CD153 - CD154 - CD155 - CD156 a, b, c - CD157 - CD158 a, d, e, i, k - CD159 a, c - CD160 - CD161 - CD162 - CD163 - CD164 - CD166 - CD167 a, b - CD168 - CD169 - CD170 - CD171 - CD172 a, b, g - CD174 - CD177 - CD178 - CD179 a, b - CD181 - CD182 - CD183 - CD184 - CD185 - CD186 - CD191 - CD192 - CD193 - CD194 - CD195 - CD196 - CD197 - CDw198 - CDw199 - CD200 201-250 CD201 - CD202b - CD204 - CD205 - CD206 - CD207 - CD208 - CD209 - CDw210 a, b - CD212 - CD213a 1, 2 - CD217 - CD218 a, b - CD220 - CD221 - CD222 - CD223 - CD224 - CD225 - CD226 - CD227 - CD228 - CD229 - CD230 - CD233 - CD234 - CD235 a, b - CD236 - CD238 - CD239 - CD240CE - CD241 - CD243 - CD244 - CD246 - CD247- CD248 - CD249 251-300 CD252 - CD253 - CD254 - CD256 - CD257 - CD258 - CD261 - CD262 - CD264 - CD265 - CD266 - CD267 - CD268 - CD269 - CD271 - CD272 - CD273 - CD274 - CD275 - CD276 - CD278 - CD279 - CD280 - CD281 - CD282 - CD283 - CD284 - CD286 - CD288 - CD289 - CD290 - CD292 - CDw293 - CD294 - CD295 - CD297 - CD298 - CD299 301-350 CD300A - CD304 - CD305 - CD307 - CD309 - CD312 - CD314 - CD315 - CD316 - CD317 - CD318 - CD320 - CD321 - CD322 - CD324 - CD325 - CD326 - CD328 - CD329 - CD331 - CD332 - CD333 - CD334 - CD335 - CD336 - CD337 - CD338 - CD339 - CD340 - CD344 - CD349 - CD350 v d e Proteins: complement system C, L, A Activators CLA: C3-convertase - C5-convertase - MAC C6, C7, C8, C9 - L: Mannan-binding lectin - A: Factor P/Properdin Enzymes C: C1Q/C1R/C1S - C4 C4a - C2 - CLA: C3 C3a, C3b/iC3b - C5 C5a - L: MASP1 - MASP2 - A: Complement factor B - Factor D Inhibitors CLA: C1-inhibitor - Decay accelerating factor - Factor I - CL: C4BP - A: Factor H Complement receptors CR1 - CR2 - CR3 - CR4 - CD11b/CD11c/CD18 - Anaphylatoxin C3a, C5a This article incorporates text from the United States National Library of Medicine, which is in the public domain. Retrieved from http://en..org/wiki/Complement_receptor_1 Categories: Genes on chromosome 1 | Human proteins | Complement system | Clusters of differentiation | Blood | Transfusion medicine | Hematology | Blood antigen systemsHidden category: Articles needing additional references from August 2008 Views Article Discussion this page History Personal tools Log in / create account Navigation Main page Contents Featured content Current events Random article Search Go Search Interaction Community portal Recent changes Contact Donate to Help Toolbox What links here Related changes Upload file Special pages Printable version Permanent link Cite this page This page was last modified on 16 August 2008, at 19:10
39 Reasons to Drink Acai Juice Every Day
What is MonaVie - Watch the 8-minute video
Discovering MonaVie video
The Power of You video
Log into your Wholesale MonaVie Account
So many of us do not eat a balanced diet, get enough sleep, have too much stress, or are impacted with toxins and pollutants. Drinking 2 ounces of MonaVie twice a day will help your body detoxify as well as build your immune system. Its the smartest thing you can do for yourself, so start today. Buying MonaVie through our company guarantees you support 7 days a week and, if you would like to share MonaVie with your family and friends we will guide you from start to finish.
1. Click on Enroll Now (30 - 55% off retail price)
2. Pay $39 for your Wholesale ID number.
3. NO minimum order required.
4. MonaVie is delivered to your door in 3 to 5 days.